Cellectis (NASDAQ:CLLS) was downgraded by stock analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research note issued on Wednesday, March 14th.
A number of other research firms have also recently weighed in on CLLS. Nomura boosted their target price on shares of Cellectis to $73.00 and gave the stock a “buy” rating in a research note on Wednesday, March 14th. Zacks Investment Research cut shares of Cellectis from a “hold” rating to a “sell” rating in a research note on Wednesday, February 14th. ValuEngine raised shares of Cellectis from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, Oppenheimer reiterated an “outperform” rating and set a $40.00 price objective on shares of Cellectis in a report on Thursday, December 28th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $42.67.
Shares of NASDAQ CLLS traded down $0.17 during mid-day trading on Wednesday, hitting $28.83. The company had a trading volume of 776,992 shares, compared to its average volume of 308,041. Cellectis has a one year low of $21.25 and a one year high of $38.85. The stock has a market capitalization of $1,189.22, a price-to-earnings ratio of -10.37 and a beta of 1.86.
Cellectis (NASDAQ:CLLS) last issued its quarterly earnings data on Monday, March 12th. The biotechnology company reported ($0.76) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.12). Cellectis had a negative return on equity of 35.63% and a negative net margin of 298.01%. The company had revenue of $6.91 million for the quarter, compared to analyst estimates of $10.10 million. sell-side analysts anticipate that Cellectis will post -2.62 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CLLS. Perceptive Advisors LLC bought a new position in Cellectis in the 4th quarter worth approximately $10,203,000. BlackRock Inc. purchased a new stake in Cellectis in the 4th quarter worth approximately $4,422,000. Sphera Funds Management LTD. lifted its stake in Cellectis by 71.1% in the 3rd quarter. Sphera Funds Management LTD. now owns 348,736 shares of the biotechnology company’s stock worth $9,922,000 after purchasing an additional 144,972 shares in the last quarter. Bain Capital Public Equity Management LLC purchased a new stake in shares of Cellectis during the 4th quarter valued at $2,848,000. Finally, Millennium Management LLC raised its position in shares of Cellectis by 1,356.2% during the 4th quarter. Millennium Management LLC now owns 104,290 shares of the biotechnology company’s stock valued at $3,040,000 after buying an additional 97,128 shares in the last quarter. 20.31% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This story was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at https://www.dispatchtribunal.com/2018/04/07/bidaskclub-downgrades-cellectis-clls-to-buy.html.
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.